On the sell side, she writes about THLD posting net losses instead of gains. Hilarious !! Is she really trying to convince us that THLD has sales? Of course they show losses each quarter !! 8-10 years of drug development costs MONEY!! during this period of time, they do not make money, they SPEND money. I guess they could have bake sales and car washes ?? It's a Late Stage Developmental drug company !! They have done extremely well in developing TH-302. 54 million dollar float is nothing for the potential that they have. The Merk deal ensures that dilution is NOT on the horizon. If approved, TH-302 will be rolling out with no more stock issuance . Dead horse needs to be put to rest. NO MORE DILUTION FOR THLD. The article is definately aimed at the Lemmings and Sheep because I can't see how any author writing for an established site such as MF could be so incredibly DUMB!
bottom line, you got it my friend.... what's she talking and misleading the people about were those one time warrants expense, repurchase that rose the EPS in last quarter's report....... on the flipside, there's another article out somewhere??????, jeezus, but headline, "poor analysts revision" of certain co's.... based on same reasons you say, bottom line, this guy gives THLD a B rating to buy.... I hear you lol....... cheers!!